Clinical and Endoscopic Outcomes After Upadacitinib Induction for Ulcerative Colitis: A Multicenter Retrospective Cohort Study

被引：8

作者：

Dalal, Rahul S. ^{[1
]}

Kallumkal, Govind ^{[2
]}

Cabral, Heidy J. ^{[1
]}

Bachour, Salam ^{[3
]}

Barnes, Edward L. ^{[4
]}

Allegretti, Jessica R. ^{[1
,5
]}

机构：

[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Gastroenterol Hepatol & Endoscopy, Boston, MA USA

[2] Univ North Carolina Chapel Hill, Dept Med, Chapel Hill, NC USA

[3] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA USA

[4] Univ North Carolina Chapel Hill, Dept Med, Div Gastroenterol, Chapel Hill, NC USA

[5] 850 Boylston St,Suite 201, Chestnut Hill, MA 02467 USA

来源：

INFLAMMATORY BOWEL DISEASES | 2023年 / 30卷 / 07期

关键词：

inflammatory bowel disease; small molecule; biologic; safety; effectiveness; MAINTENANCE THERAPY;

D O I：

10.1093/ibd/izad155

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

In this retrospective cohort study, upadacitinib induction was effective in achieving steroid-free clinical remission of ulcerative colitis for the majority of patients. Adverse events leading to treatment discontinuation were rare and were consistent with the known safety profile of upadacitinib.

引用

页码：1207 / 1210

页数：4

共 8 条

[1] Comparative Effectiveness of Upadacitinib and Tofacitinib in Inducing Remission in Ulcerative Colitis: Real-World Data [J].

Boneschansker, Leo ;

Ananthakrishnan, Ashwin N. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (09) :2427-+

[2]

Cohen SB, 2021, ANN RHEUM DIS, V80, P304, DOI [10.1136/annrheumdis-2020-218510, 10.1136/annrheumdis-2020-218510.]

[3]

Danese S, 2022, LANCET, V399, P2113, DOI [10.1016/s0140-6736(22)00581-5, 10.1016/S0140-6736(22)00581-5]

[4] Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience [J].

Friedberg, Scott ;

Choi, David ;

Hunold, Thomas ;

Choi, Natalie K. ;

Garcia, Nicole M. ;

Picker, Emma A. ;

Cohen, Nathaniel A. ;

Cohen, Russell D. ;

Dalal, Sushila R. ;

Pekow, Joel ;

Sakuraba, Atsushi ;

Cleveland, Noa Krugliak ;

Rubin, David T. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (07) :1913-+

[5] Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors [J].

Goetsch, Alexander ;

D'Amico, Ferdinando ;

Allocca, Mariangela ;

Fiorino, Gionata ;

Furfaro, Federica ;

Zilli, Alessandra ;

Parigi, Tommaso Lorenzo ;

Radice, Simona ;

Peyrin-Biroulet, Laurent ;

Danese, Silvio .

EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (07) :849-861

[6] Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis [J].

Lasa, Juan S. ;

Olivera, Pablo A. ;

Danese, Silvio ;

Peyrin-Biroulet, Laurent .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (02) :161-170

[7] In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494) [J].

Parmentier J.M. ;

Voss J. ;

Graff C. ;

Schwartz A. ;

Argiriadi M. ;

Friedman M. ;

Camp H.S. ;

Padley R.J. ;

George J.S. ;

Hyland D. ;

Rosebraugh M. ;

Wishart N. ;

Olson L. ;

Long A.J. .

BMC Rheumatology, 2 (1)

[8] Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis [J].

Sandborn, William J. ;

Su, Chinyu ;

Sands, Bruce E. ;

D'Haens, Geert R. ;

Vermeire, Severine ;

Schreiber, Stefan ;

Danese, Silvio ;

Feagan, Brian G. ;

Reinisch, Walter ;

Niezychowski, Wojciech ;

Friedman, Gary ;

Lawendy, Nervin ;

Yu, Dahong ;

Woodworth, Deborah ;

Mukherjee, Arnab ;

Zhang, Haiying ;

Healey, Paul ;

Panes, Julian .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (18) :1723-1736

← 1 →